Studies have shown that decreased expression of a key glutamate receptor, GLT-1, in both AD and Huntington’s disease (HD) patients and related rodent disease models reduces the efficiency of glutamate uptake by astrocytes for release into the synaptic cleft (Andersen et al., 2021). Here, SLC1A2 is linked to Huntington disease.